Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

RSV vaccine programme to roll out in pharmacies this autumn

Elderly patients will be eligible to receive the respiratory syncytial virus (RSV) vaccine from September 1 in some community pharmacies, the government has announced.

Patients aged 75 to 79 and all women who are at least 28 weeks pregnant can receive a single dose of the RSV vaccine starting September 1, NHS England (NHSE) and the UK Health Security Agency (UKHSA) announced last week (June 24).

The programme aims to protect older adults, neonates and small babies who are at higher risk from RSV and its complications, a letter to healthcare professionals and commissioners said.

It added that NHSE will commission “a number of” community pharmacies to deliver the “older adults” programme, as well as local GP practices - with further details to be “shared in due course”.

Read more: Private pharmacy RSV and dengue fever vaccine services launch in UK 'first'

It remains unclear how many pharmacies will be commissioned to deliver the service and how much they will be paid.

This comes after the Joint Committee on Vaccination and Immunisation (JCVI) again recommended that “older adults and infants” must be protected against RSV, an NHS spokesperson said.

“The NHS will pull out all the stops to ensure that people have protection against this nasty virus ahead of winter, with GPs preparing to offer this new vaccine to vulnerable groups as quickly as possible,” they added.

 

Who is eligible?

 

All adults turning 75 years old on or after September 1 will be eligible for the routine programme and should be offered a single dose of the RSV vaccine on or after their 75th birthday, the letter said.

Meanwhile, patients already aged 75 to 79 on September 1 should be vaccinated via a “one-off catch-up campaign” at the “earliest opportunity with the aim of completing the majority” by August 31 2025, it added.

Individuals will remain eligible “until the day before their 80th birthday”, except those who turn 80 in the first year who have until August 31 2025 to get vaccinated, it said.

Read more: JCVI recommends RSV vaccination programme for babies and over-75s

And it added that providers should “vaccinate as many people as possible during September and October 2024 prior to the expected RSV season” to “offer the best protection”.

The letter also said that all women who are “at least” 28 weeks pregnant on or after September 1 will be offered a single dose of the jab and will be eligible until birth.

It added that the “ideal opportunity” to offer the RSV vaccine is at the 28-week antenatal contact (ANC) and that maternity service providers should aim to vaccinate pregnant women eligible on September 1 as “soon as possible”.

Read more: UK’s first private pharmacy COVID-19 vaccine service launched today

RSV is a “common respiratory virus that can cause serious lung infections” and has a “considerable impact” on individuals and NHS services during the winter months, the letter said.

In October, C+D revealed that the UK’s first private RSV vaccination service package had launched in community pharmacies.

Related Content

Topics

         
Pharmacy Manager
Guernsey
£70,000

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD138317

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel